Wallach David, Engelmann Hartmut, Aderka Dan, Rubinstein Menachem: (tnf)Inhibitory protein and its purification.. Yeda Res & Dev, March 22, 1989: EP0308378-A2 (128 worldwide citation)

Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified. It has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF. TNF Inhibitory Protein, salts, functional derivatives and active fractions thereof and mixtures of any o ...

Wallach David: A monoclonal antibody recognizing a cytotoxin, a hybridoma cell line expressing same and a process for the preparation of a purified cytotoxin.. Yeda Res & Dev, July 9, 1986: EP0186833-A2 (121 worldwide citation)

A cytotoxic protein expressed by human peripheral blood mononuclear cells is isolated in essentially homogenous form. This protein may be used to elicit production of polyclonal or monoclonal anti-cytotoxin antibodies. Hybridomas secreting anti-cytotoxin antibodies are identified by a solid phase bi ...

Yayon Avner, Nevo Zvi: Fgfr3 as a marker for mesenchymal skeletal progenitor cells. Yeda Res & Dev, Univ Ramot, April 8, 1998: EP0833620-A1 (111 worldwide citation)

The present invention concerns fibroblast growth factor 9 (FGF9) as a high affinity ligand for fibroblast growth factor receptor 3 (FGFR3) which ligand is capable of binding and activating FGFR3 in a specific manner. The present invention is also directed to methods for detection of FGFR3 by utilizi ...

Wallach David, Brakebusch Cord: Multimers of the soluble forms of tnf receptors, their preparation and pharmaceutical compositions containing them.. Yeda Res & Dev, February 10, 1993: EP0526905-A2 (108 worldwide citation)

Multimers of the soluble forms of the tumor necrosis factor receptors (TNF-Rs) are provided. These multimers are produced either by chemical or by recombinant methods. The multimers of the soluble forms of TNF-Rs are useful for protecting mammals (including humans) from the deleterious effects of TN ...

Wallach David, Engelmann Hartmut, Aderka Dan, Novick Daniela, Rubinstein Menachem: Tumor necrosis factor binding protein ii, its purification and antibodies thereto.. Yeda Res & Dev, November 22, 1990: EP0398327-A1 (106 worldwide citation)

Tumor Necrosis Factor (TNF) Binding Protein is isolated and substantially purified. It has the ability to inhibit the cytotoxic effect of TNF and/or to maintain its prolonged beneficial effects. TNF Binding Protein II and salts, functional derivatives, precursors and active fractions thereof can be ...

Wallach David, Nophar Yaron, Kemper Oliver, Engelmann Hartmut, Brakebusch Cord, Aderka Dan: Expression of the recombinant tumor necrosis factor binding protein i (tbp-i).. Yeda Res & Dev, June 26, 1991: EP0433900-A1 (100 worldwide citation)

Tumor Necrosis Factor Binding Protein I (TBP-I), precursors and analogs thereof, are produced by transfecting eukaryotic cells with an expression vector comprising a DNA molecule encoding the whole human type I TNF receptor or a soluble domain thereof, and culturing the transfected cells, whereby th ...

Wallach David, Engelmann Harmut, Aderka Dan: (ab) Fragments thereof.. Yeda Res & Dev, February 13, 1991: EP0412486-A1 (81 worldwide citation)

Antibodies to TNF Binding Protein I (TBP-I) and F(ab) fragments thereof are provided that can be used in diagnostic assays and pharmaceutical agents for either inhibiting or mimicking the effects of TNF on cells.

Bohak Zvi, Kadouri Avinoam, Sussman Martin: A matrix for cell cultivation in vitro. Yeda Res & Dev, February 11, 1987: GB2178447-A (61 worldwide citation)

A matrix and cultivation system for anchorage dependent cells has a substantially increased available effective surface area for cell attachment provided by a fiber network or open-pore foams with suitable pore size of 10 mu to 100 mu . Attachment of the cells can be enhanced by modifying the surfac ...

Revel Michel, Rubinstein Menachem, Mory Yves, Chen Louise, Novick Daniela, Michalevicz Rita: Human ifn-beta2/il-6, its purification and uses.. Yeda Res & Dev, August 2, 1989: EP0326120-A2 (56 worldwide citation)

Monoclonal antibodies to IFN- beta 2/IL-6 and hybridomas producing them and production and purification of glycosylated and unglycosylated IFN- beta 2/ IL-6 are disclosed. The protein is useful in the treatment of breast cancer, leukemia, infectious diseases and bone marrow progenitor cell disorders ...